Protection of renal function in diabetics;Protektion der nierenfunktion bei diabetikern

Internist

Volumn 48, Issue 7, 2007, Pages 686-697

  Hasslacher, C ^a,b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Diabetes; Nephropathy; Primary prevention; Secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HEMOGLOBIN A1C; LISINOPRIL; PLACEBO; RENIN INHIBITOR;

ANEMIA; CARDIOVASCULAR RISK; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; METABOLIC REGULATION; MICROALBUMINURIA; MORBIDITY; PRIMARY PREVENTION; PROTEIN INTAKE; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SECONDARY PREVENTION; SMOKING;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY FUNCTION TESTS; LIFE STYLE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 39649098443     PISSN: 00209554     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00108-007-1894-x     Document Type: Review

References (48)

1. Hasslacher C, Kempe P, Ritz E et al. (2007) Praxisleitlinie Diabetische Nephropathie. Diabetologie 2 (Suppl 2): S159-S162
2. The Diabetes Control and Complications Trial Research Group (1995) Effect of intensive therapy on the development and progression of diabetic nephropathy in the diabetes control and complications trial. Kidney Int 47: 1703-1720
3. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2000) Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342: 381-389
4. Ohkubo Y, Kishikawa H, Araki E et al. (1995) Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus; a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117
5. UK Prospective Diabetes Study Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2-diabetes(UKPDS 33). Lancet 352: 837-853
6. Lindholm L, Ibsen H, Dahlöf B et al. (2002) Cardiovascular morbidity and mortality in patients with diabetes in the Losartan intervention für endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 1004
7. Ruggenenti P, Ilieva A, Bruno S (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351: 1941-1951
8. Stratton IM, Cull CA, Adler AI (2006) Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia 49: 1761-1769
9. The EUCLID Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349: 1787-1792
10. Ravid M, Brosh D, Levi Z et al. (1998) Use of Enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. Ann Intern Med 128: 982-988
11. Heart Outcomes Prevention Evaluation Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259
12. Scott U, Warram JH, Hanna LS (2001) A nonlinear effect of hyperglycemia and current cigarette smoking are major determinants of the onset of microalbuminuria in type 1 diabetes. Diabetes 50: 2842-2849
13. Klein R, Klein BEK, Moss SE (1993) Incidence of gross proteinuria in older-onset diabetes. A population-based perspective. Diabetes 42: 381-389
14. Thomas MC, Rosengard-Bärlund M, Forsblom C (2006) Serum lipids and the progression of nephropathy in type 1 diabetes. Diabetes Care 29: 317-322
15. Wang PH (1997) When should ACE inhibitors be given to normotensive patients with IDDM. Lancet 349: 1782
16. Ravid M, Savin H, Jutrin I et al. (1993) Long-term stabilizing effect of Angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type 2 diabetic patients: Ann Intern Med 118: 577-581
17. Ahmad J, Siddiqui M, Ahmad H (1997) Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 20: 1576-1581
18. Hasslacher C (2006) Metabolische Kontrolle bei diabetischer Nephropathie. Diabetologe 2: 410-418
19. Peterson JC, Adler S, Burkart JM (1995) Blood pressure control, proteinuria, and the progression of renal disease: the modification of diet in renal disease study. Ann Intern Med 123: 754-762
20. Strippoli G, Craig M, Deeks J (2004) Effects of angiotensin converting enzyme inhibitors and angiosin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 329: 828
21. Barnett AH, Bain SC, Bouter P (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351: 1952-1961
22. Mogensen C, Neldam St, Tikkanen I et al. (2000) Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study: BMJ 321: 1440-1444
23. Rossing K, Jacobsen P, Pietraszek L (2003) Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy. Diabetes Care 26: 2268-2274
24. Nakao N, Yoshimura A, Morita H et al. (2003) Combination treatment of angiotensin II receptor blocker and angiotensin converting enzyme inhibitor in non-diabetic renal disease (COOPERATE). Lancet 361: 117-124
25. Nyberg G, Blohme G, Nordern G (1987) Impact of metabolic control in progression of clinical diabetic nephropathy. Diabetologia 30: 82-86
26. Hasslacher C, Bostedt-Kiesel A, Kempe H et al. (1993) Effect of metabolic factors and blood pressure on kidney function in proteinuric Type 2 (non-insulin dependent) diabetic patients. Diabetologia 36: 1051-1056
27. Manto A, Cortroneo P, Marra G et al. (1995) Effect of intensive treatment in diabetic nephropathy in patients with type 1 Diabetes. Kidney Int 47: 231-235
28. Mai-Szu Wu, Chun-Chen Yu, Chih-Wei Yang et al. (1997) Poor pre-dialysis glycaemic control is a predictor of mortality in type 2 diabetic patients on manintenance haemodialysis. Nephrol Dial Transplant 12: 2105-2110
29. Warram JH, Scott LJ, Hanna LS et al. (2000) Progression of microalbuminuria to proteinuria in type 1 diabetes; Nonlinear relationship with hyperglycemia. Diabetes 49: 94-98
30. Sarafidis PA, Bakris GL (2006) Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70: 1223-1233
31. Rave K, Heise T, Pfützner A et al. (2001) Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 24: 886-890
32. Sawicki PT, Didjurgeit U, Mühlhauser I et al. (1994) Smoking is associated with progression of diabetic nephropathy. Diabetes Care 17: 126-131
33. Biesenbach G, Janko O, Zazgornik J (1994) Similar rate of progression in the predialysis phase in type 1 and type 2 diabetes mellitus. Nephrol Dial Transplant 9: 1097-1102
34. Zeller K, Whittaker E, Sullivan L et al. (1991) Effect of restricting dietary protein on the progression of renal failure in patients with insulin dependent diabetes mellitus. N Engl J Med 324: 78-84
35. Hansen HP, Tauber-Lassen E, Jensen BR et al. (2002) Effect of dietary protein restriction on prognosis with diabetic nephropathy. Kidney Int 62: 220-228
36. Hasslacher C (2004) Prävalenz und Schweregrad einer Anämie bei Diabetikern mit eingeschränkter Nierenfunktion. Diab Stoffw 13: 181-185
37. Thomas MC (2007) Anemia in diabetes: marker or mediator of microvascular disease. Nat Clin Pract Nephrol 3: 20-30
38. Babazono T, Hanai K, Suzuki K (2006) Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia 49: 1387-1393
39. Drüeke TB, Locatelli F, Clyne N (2006) Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071-2084
40. Singh AK, Szczech L, Tang KL (2006) Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085-2098
41. Tonelli M, Keech A, Shepherd J (2005) Effect of pravastatin on people with diabetes and chronic kidney disease. J Am Soc Nephrol 16: 3748-3754
42. Wanner C, Krane V, März W (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysios. N Engl J Med 353: 238-248
43. Douglas K, O'Malley PG, Jackson J (2006) Meta-analysis: the effect of statins on albuminuria. Ann Intern Med 145: 117-124
44. Collins R, Armitage J, Parish S (2003) Heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 2005-2016
45. De Zeeuw D, Remuzzi G, Parving HH et al. (2004) Proteinuria, a target for renoprotection in patients with type2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65: 2309-2320
46. De Zeeuw D, Remuzzi G, Parving HH et al. (2004) Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110: 921-927
47. Feld-Rasmussen B, Mathiesen ER, Jensen T et al. (1991) Effect of improved metabolic control on loss of kidney function in type 1 (insulin-dependent) diabetic patients: an update of the Steno studies. Diabetologia 34: 164-170
48. Gaede P, Vedel P, Parving HH et al. (1999) Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 353: 617-622